Blockade of CTLA-4 promotes the development of effector CD8(+) T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.
The development of cancer immunotherapy has long been a challenge. Here, we report that prophylactic vaccination with a highly attenuated Trypanosoma cruzi strain expressing NY-ESO-1 (CL-14-NY-ESO-1) induces both effector memory and effector CD8(+) T lymphocytes that efficiently prevent tumor develo...
Main Authors: | Dos Santos, L, Galvão-Filho, B, de Faria, P, Junqueira, C, Dutra, MS, Teixeira, S, Rodrigues, M, Ritter, G, Bannard, O, Fearon, D, Antonelli, L, Gazzinelli, RT |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Berlin Heidelberg
2015
|
Similar Items
-
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
by: Chen, J, et al.
Published: (2015) -
Intracellular delivery of radioimmunoconjugates that target the cancer testis antigen, NY-ESO-1
by: Chu, H
Published: (2013) -
NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses.
by: Wadle, A, et al.
Published: (2010) -
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.
by: Gnjatic, S, et al.
Published: (2000) -
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
by: Jäger, E, et al.
Published: (2000)